Multi-Omics in Biomarker Discovery & Precision Medicine
Online Symposium
12 November 2024 | Online, GMT (UTC+0)
Bringing together key opinion leaders from across the globe for focused discussions on utilising multi-omics approaches in biomarkers discovery & precision medicine
Sponsored By
Sapient is a biomarker discovery organization providing bespoke services for proteomics, metabolomics, and lipidomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data; robust quality control analysis; and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.
Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial molecular biology solutions, including instruments, assays, software, and services to support life sciences research. By integrating technologies from NanoString and Canopy Biosciences, Bruker offers an extensive portfolio designed to meet the diverse needs of global researchers exploring spatial biology. The CosMx® Spatial Molecular Imager (SMI) enables high-plex detection and analysis of over 6,000 RNAs with single-cell resolution and precise cell segmentation, supported by the cloud-based AtoMx™ Spatial Informatics Platform. The GeoMx® Digital Spatial Profiler is a leading platform for whole-tissue exploration, providing whole transcriptomics and high-plex proteomic readouts. The CellScape™ Precise Spatial Proteomics platform allows for high-plex protein expression analysis at single-cell resolution, using versatile, open-sourced reagents. The nCounter® Analysis System enables rapid quantification of profiling of gene and miRNA expression with high sensitivity. Together, Bruker Spatial Biology’s solutions are supported by a strong team of scientists, sales, and service associates, along with Canopy Multiomic Services for biopharmaceutical research, assay development, and clinical sample testing. For more information, visit www.BrukerSpatialBiology.com.
Codetta BioTM is a leader in developing cutting-edge multi-omic biomarker measurement tools, empowering data-driven insights into the unique genetic, environmental, lifestyle, and clinical factors that shape individual health and wellness. At Codetta Bio, we are committed to driving innovation and creating positive changes in the protein and nucleic acid fields. Our state-of-the-art tools revolutionize biomarker assays, offering scale and plex capabilities that rival traditional digital and quantitative PCR methods. Uniquely, our technology requires only one instrument for the analysis of both proteins and nucleic acids, simplifying the process and reducing costs. Through our dedication to technological advancement and scientific excellence, we support a deeper understanding of health and disease, ensuring we remain at the forefront of multi-omic biomarker measurement.
Key Topics Covered
- Best practice multi-omics approaches for advanced biomarker discovery:
» Proteomics
» Transcriptomics - Incorporating immunoprofiling into omics-based approaches
- Spatial multi-omics in biomarker discovery research
- Integrating biomarker discovery into drug discovery processes
- Multi-omics analysis in precision medicine
Benefits of Attending
- Meet with global key innovators in a focused symposium to hear the latest case studies in utilizing multi-omics for biomarker discovery & precision medicine. This programme takes a deep dive into best practice multi-omics approaches & technological advancements, bringing together thought leaders from across the globe for focused discussions & networking
- Stay at the forefront of innovation by hearing about the latest methods & strategies of integrating spatial multi-omics in biomarker discovery research
- Discuss the latest advancements in multi-omics analysis in precision medicine
- Followed by the release of the ‘Harnessing Biomarker Discovery & Precision Medicine with Multi-Omics-Based Approaches’ report detailing key insights, methodologies,
and emerging trends discussed during the event for leveraging biomarkers discovery effectively
Oxford Global's online symposiums serve as hubs for professionals to connect, share knowledge, and inspire innovation. By bringing together experts from all geographies, we create dynamic environments where cutting-edge ideas are exchanged and boundaries are pushed. Our symposiums are highly focused, delving deep into specific topics to provide valuable insights and expertise. Through collaborative discussions and forward-thinking initiatives, we inspire new approaches and drive progress in life sciences. Join us to be part of this transformative journey towards groundbreaking discoveries and solutions!
Latest Resources
Imaging Starts Using Brand New Radiotracer from Nuclidium
The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer.
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Meet Our Expert Speakers
Multi-Omics in Biomarker Discovery & Precision Medicine Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Claudia Fredolini
Head of Unit,
SciLifeLab
Jia Guo
Associate Professor,
Arizona State University
Manuel Salto-Tellez
Professor,
The Institute of Cancer Research
Priyank Patel
Senior Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Register Your Interest
Submit your details and a member of our team will be in touch